



Cellumen Establishes Collaboration in Breast Cancer Patient Stratification

Pittsburgh, PA, October 1, 2007. Cellumen, Inc. and Mayo Foundation for Medical Education and Research announced today the formation of a collaboration to apply cellular systems biology (CSB™) profiling to breast cancer patient stratification. The goal is to create a breast cancer patient profile test to improve diagnosis and treatment for individualized medicine.

“We are very pleased to initiate an exciting research and development program with Mayo, a leader in individualized medicine,” stated D. Lansing Taylor, Ph.D, CEO of Cellumen. “We are treating breast tumors as a “system” within the breast cancer patient. A combination of breast cancer biomarkers and migratory immune cell biomarkers are being multiplexed in tissue micro-array (TMA) samples.

“We are enthusiastic about the synergy between Cellumen and Mayo in approaching this challenging opportunity,” stated Taylor, “Mayo has great expertise and experience that will be applied to this collaboration. Cellumen continues to develop collaborations with the best in class partners to bring CSB solutions to the market.”

About Cellumen

Cellumen, Inc. is the Cellular Systems Biology Company. Cellumen focuses on the cell as an integrated and interacting network of genes, proteins and metabolites responsible for normal and abnormal (disease) function. To promote efficient drug discovery and development, the company offers solutions to the dual challenges of efficacy and toxicity. The company’s products and services have application in each of the major segments of the pharmaceutical pipeline: drug discovery (“cellular models of disease”), drug development (“cytotoxicity profiling”) and clinical trials (“patient sample profiling”). The Cellumen team leverages its experience and expertise in High Content Screening, cell-based assays, advanced reagents and bioinformatics to create high value solutions. www.cellumen.com.